AS01B佐剂乙型肝炎疫苗全身反应原性与炎症参数关联的事后分析
一项II期随机试验纳入60名18-45岁乙型肝炎未感染成人,比较HBsAg-AS01B与HBsAg-Alum疫苗的反应原性和先天免疫参数。事后分析发现,AS01B组CRP、胆红素、白细胞、单核细胞和中性粒细胞计数快速短暂升高,全身症状与CRP、IL-6升高相关;第二剂后CRP、IL-6、IP-10、IFN-γ、MIP-1β和MCP-2为关键关联参数。结论提示IL-6和IFN-γ信号与AS01B佐剂疫苗全身反应原性相关,且与免疫原性信号相似。
要点
- AS01B佐剂疫苗全身症状与CRP、IL-6升高相关。
- 第二剂后CRP、IL-6、IP-10、IFN-γ等为关键关联参数。
- 反应原性与免疫原性可能共享先天免疫信号。
核心结论
- IL-6和IFN-γ信号与AS01B佐剂疫苗接种后全身反应原性相关。
- 这些信号与既往HBsAg佐剂疫苗诱导抗体和T细胞应答相关信号相似,提示反应原性与免疫原性可能基于相似的先天免疫信号。
研究设计与样本
- II期随机试验事后分析,60名18-45岁乙型肝炎未感染成人按1:1随机接受两剂HBsAg-AS01B(D0和D30)或三剂HBsAg-Alum(D0、D30、D180)。
- 接种前所有受试者接受安慰剂注射以区分注射过程和疫苗接种的影响。
- 主要结局包括接种后反应原性症状、生命体征、血细胞因子、生化和血液学参数,采用线性回归探索关联。
- 使用来自既往HBsAg佐剂疫苗免疫应答研究(NCT00805389)的独立数据集验证观察结果。
主要发现
- AS01B疫苗诱导的HBsAg特异性抗体水平高于Alum。
- 接受HBsAg-AS01B/Alum疫苗或安慰剂的个体局部和全身症状更频繁,但轻微且短暂。
- AS01B组接种后血CRP、胆红素、白细胞、单核细胞和中性粒细胞计数快速短暂升高,Alum或安慰剂组无此变化。
- AS01B组淋巴细胞计数下降,Alum组乳酸脱氢酶水平下降。
- 首次HBsAg-AS01B或HBsAg-Alum免疫后,全身症状与CRP和IL-6水平升高相关;第二剂后CRP、IL-6、IP-10、IFN-γ、MIP-1β和MCP-2为关键关联参数。
临床怎么用
- 接种AS01B佐剂乙肝疫苗后出现全身症状时,可结合CRP、IL-6等炎症参数理解反应原性,但当前证据尚不足以用于临床决策。
局限性
- 本研究为事后分析,样本量60例,结果需更大样本验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Adjuvants like AS01B increase the immunogenicity of vaccines and generally cause increased transient reactogenicity compared with Alum. A phase II randomized trial was conducted to characterize the response to AS01B and Alum adjuvanted vaccines. A post-hoc analysis was performed to examine the associations between reactogenicity and innate immune parameters. METHODS: The trial involved 60 hepatitis B-naïve adults aged 18-45 years randomized 1:1 to receive either two doses of HBsAg-AS01B on Day (D)0 and D30, or three doses of HBsAg-Alum on D0, D30, D180. Prior to vaccination, all subjects received placebo injection in order to differentiate the impact of injection process and the vaccination. Main outcomes included reactogenicity symptoms, vital signs, blood cytokines, biochemical and hematological parameters after vaccination. Associations were explored using linear regression. FINDINGS: The vaccine with AS01B induced higher HBsAg-specific antibody levels than Alum. Local and systemic symptoms were more frequent in individuals who received HBsAg AS01B/Alum vaccine or placebo, but were mild and short-lived. Blood levels of C-reactive protein (CRP), bilirubin, leukocyte, monocyte and neutrophil counts increased rapidly and transiently after AS01B but not after Alum or placebo. Lymphocyte counts decreased in the AS01B group and lactate dehydrogenase levels decreased after Alum. Modelling revealed associations between systemic symptoms and increased levels of CRP and IL-6 after the first HBsAg-AS01B or HBsAg-Alum immunization. Following the second vaccine dose, CRP, IL-6, IP-10, IFN-γ, MIP-1β and MCP-2 were identified as key parameters associated with systemic symptoms. These observations were confirmed using an independent data set extracted from a previous study of the immune response to HBsAg-adjuvanted vaccines (NCT00805389). CONCLUSIONS: IL-6 and IFN-γ signals were associated with systemic reactogenicity following administration of AS01B-adjuvanted vaccine. These signals were similar to those previously associated with antibody and T-cell responses induced by HBsAg-adjuvanted vaccines, suggesting that similar innate immune signals may underlie adjuvant reactogenicity and immunogenicity. TRIAL REGISTRATION: www.clinicaltrials.gov NCT01777295.
引用
- Burny W, Marchant A, Hervé C, et al. Inflammatory parameters associated with systemic reactogenicity following vaccination with adjuvanted hepatitis B vaccines in humans. Vaccine. 2019. PMID: 30850240. doi:10.1016/j.vaccine.2019.02.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。